The Motley FoolAug 31, 11:22 AM ET▲ Positive
Up 64% year-to-date in 2026 and nearly doubled over the past year, significantly outperforming most other Ark ETFs. Strong market for biotechs and gene-editing stocks has fueled substantial gains.
Cboe BZX · ARKG
ARK Genomic Revolution ETF news
$53.35−0.02%
Close Sep 28, 2026 · split-adjustedArticles · 30 days1English, de-duplicated
Positive1100% of coverage
Neutral00%
Negative00% of coverage
About ARK Genomic Revolution ETF
No recent articles focused on ARK Genomic Revolution ETF.
Also mentions ARKG
Articles that tag ARKG but are mainly about other companies.
The Motley FoolJul 22, 5:30 AM ET▲ Positive
The ETF holds $92 million in CRISPR Therapeutics, further demonstrating Ark's confidence in gene-editing and genomic innovation as a long-term investment theme.
The Motley FoolJul 19, 4:12 PM ETNeutral
Similar to Ark Innovation ETF, this is executing standard portfolio rebalancing by trimming a large position to reallocate capital.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology